# pharma&

Source: https://onco.cc/companies/pharmaand/  
OnCo record `pharmaand` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

pharma& is a Vienna company that buys and markets established medicines, including the PARP inhibitor rucaparib (Rubraca), which it acquired from Clovis Oncology's bankruptcy in 2023.

## Summary

pharma& (pharmaand GmbH), based in Vienna, acquires and commercialises marketed medicines rather than developing new molecules. In oncology it bought rucaparib (Rubraca), the PARP inhibitor approved for BRCA-mutated ovarian and prostate cancer, from Clovis Oncology in 2023 after Clovis filed for bankruptcy, and it now holds the US and EU authorisations and runs the remaining trials and post-marketing commitments. It appears on OnCo as an FDA oncology applicant and a phase 3 trial sponsor on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: pharmaand GmbH; pharma& GmbH; pharmaand
- Tags: ctgov-sponsor
- HQ: Vienna
- Type: pharma
- Website: https://www.pharmaand.com

## Sources

- Official website: https://www.pharmaand.com
- ClinicalTrials.gov: trials led by pharmaand: https://clinicaltrials.gov/search?lead=pharmaand

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Rucaparib](https://onco.cc/drugs/rucaparib/)
- companies: [Clovis Oncology](https://onco.cc/companies/clovis-oncology/)

---
JSON: https://onco.cc/api/v1/entities/pharmaand.json